Press monitoring
Bionor files first clinical trial application for BIOSKILL
17.11.2015 | Press monitoring
Oslo, Norway, 17 November 2015 - Bionor Pharma ASA (OSE:BIONOR) today announced the submission of a clinical trial application (CTA) to the Danish Medicines Agency requesting approval to initiate BIOSKILL in Denmark. BIOSKILL ( BIO nor Shock and KILL ) will enroll patients internationally and further CTAs will be submitted to national medicines...
Scientists publish unique genomic discoveries with SMRT
16.11.2015 | Press monitoring
A new paper released in Nature today reported the virtually complete draft genome of Oropetium thomaeum, a grass species that can regrow after exposed to extreme drought when water becomes available. The plant's 245 Mb genome was analyzed with 72x coverage on the PacBio RS II sequencing system by Donald Danforth Plant Science Center researchers...
Alcon introduces Contoura Vision as first personalized LASIK procedure at American Academy of Ophthalmology Annual Meeting
15.11.2015 | Press monitoring
Basel, November 15, 2015 - Alcon, the global leader in eye care and a division of Novartis, will introduce Contoura Vision, the latest advancement in its WaveLight refractive portfolio during the annual meeting of the American Academy of Ophthalmology (AAO) in Las Vegas, November 14-17, 2015. Alcon will also present new research findings in...
IBA Signs Final Contracts to Install Three Compact Proton Therapy Centers in the United Kingdom
13.11.2015 | Press monitoring
Louvain-la-Neuve, Belgium, November 13, 2015 - IBA (Ion Beam Applications S.A.), the world's leading provider of proton therapy solutions for the treatment of cancer, has signed contracts with Proton Partners International (PPI) to install three Proteus ® ONE compact proton therapy systems in private clinics in the United Kingdom: one in Newport...
Finnish Medicines Agency authorization of first-in-man clinical study with Lymfactin
13.11.2015 | Press monitoring
Finnish Medicines Agency Fimea has authorized Herantis Pharma Plc's ("Herantis") first-in-man clinical study of Lymfactin® for the treatment of breast-cancer associated lymphedema. Patient recruitment in the clinical study is planned to begin in Finland in the first half of 2016.
Engineered bat virus stirs debate over risky research
13.11.2015 | Press monitoring
An experiment that created a hybrid version of a bat coronavirus – one related to the virus that causes SARS (severe acute respiratory syndrome) – has triggered renewed debate over whether engineering lab variants of viruses with possible pandemic potential is worth the risks. In an article published in Nature Medicine, scientists investigated a...
Ekso Bionics(R) to Establish Headquarters in Freiburg, Germany; Strengthens European Expansion Efforts
12.11.2015 | Press monitoring
RICHMOND, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) - Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a leading global robotic exoskeleton company, announced today that it has established a new regional headquarters, based in Freiburg, Germany, to further strengthen its European presence and better serve German-speaking markets. The expansion is being led...
Navamedic to launch non-invasive prenatal tests in Nordic markets
12.11.2015 | Press monitoring
Navamedic ASA (OSE: NAVA), the Norwegian medtech and pharmaceutical products company, announced today an agreement signed with Sequenom Laboratories of USA, a leading molecular diagnostics laboratory, for the launch of three non-invasive prenatal genetic tests in the Nordic region.
Leukaemia success heralds wave of gene-editing therapies
11.11.2015 | Press monitoring
Layla, a one-year-old girl with leukaemia, is in remission thanks to gene-editing technology that allowed her to receive modified immune cells from another person. Her case represents the second trial of gene-editing as a therapy – the first was carried out last year in patients with HIV. More similar trials are planned – and companies are also...
MDxHealth to Participate in Prospective Clinical Validation Study with AssureMDx for Bladder Cancer
9.11.2015 | Press monitoring
IRVINE, CA, and HERSTAL, BELGIUM, November 10, 2015 - MDxHealth SA (Euronext: MDXH), announced today that it has entered into an agreement with Erasmus University Medical Center Rotterdam (Erasmus MC) for the inclusion of MDxHealth's AssureMDx for Bladder Cancer, a urine-based, liquid biopsy test, into a prospective clinical study designed to...
